Recent discoveries related to PFK-2 isozymes, especially PFKFB3 and PFKFB4, in cancer progression and development, have identified their inhibitors as potent therapeutic agents that could play an important role in future cancer treatment. This evidence concerns the gene PFKFB3 and cancer.